HIV-1 RNA Kinetics in Blood Plasma and in Seminal Plasma of Men Starting a Dolutegravir-Based Triple-Combination Regimen at the Time of Primary HIV-1 Infection.
Adult
Anti-HIV Agents
/ therapeutic use
HIV Infections
/ drug therapy
HIV-1
/ genetics
Heterocyclic Compounds, 3-Ring
/ therapeutic use
Humans
Kinetics
Male
Middle Aged
Oxazines
/ therapeutic use
Piperazines
/ therapeutic use
Pyridones
/ therapeutic use
RNA, Viral
/ genetics
Semen
/ virology
Viral Load
HIV-1
dolutegravir
drug concentration
primary HIV infection
seminal plasma
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
05 01 2022
05 01 2022
Historique:
received:
04
04
2021
accepted:
22
06
2021
pubmed:
25
6
2021
medline:
24
2
2022
entrez:
24
6
2021
Statut:
ppublish
Résumé
We compared the proportion of participants achieving first undetectable HIV-1 RNA (VL) in seminal plasma (SP) and blood plasma (BP) in 19 men starting dolutegravir-based regimen at primary HIV infection. At baseline, median VL was 6.5 (interquartile range [IQR], 5.6-7.9) and 4.5 (IQR, 3.5-5.0) log10 copies/mL in BP and SP, respectively. Between baseline and week 48, significantly higher proportion of participants achieved first VL below limit of quantification in SP (93.0%) than in BP (84.2%; P = .008). Time to first undetectable VL was 8 weeks in SP (95% confidence interval [CI], 5.6-10.4) and 24 weeks in BP (95% CI, 14.1-33.9).
Identifiants
pubmed: 34166492
pii: 6309026
doi: 10.1093/infdis/jiab336
doi:
Substances chimiques
Anti-HIV Agents
0
Heterocyclic Compounds, 3-Ring
0
Oxazines
0
Piperazines
0
Pyridones
0
RNA, Viral
0
dolutegravir
DKO1W9H7M1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
116-120Informations de copyright
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.